Journal of Cardiovascular Imaging

Korean Society of Echocardiography (한국심초음파학회)
권호 표지
DOI QR코드

DOI QR Code

Statins Have No Role in Preventing the Progression of Aortic Valve Sclerosis

  • Seo, Jeong-Hun (Department of Internal Medicine, Kangwon National University Hospital) ;
  • Chun, Kwang-Jin (Division of Cardiology, Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine) ;
  • Lee, Bong-Ki (Division of Cardiology, Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine) ;
  • Cho, Byung-Ryul (Division of Cardiology, Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine) ;
  • Ryu, Dong Ryeol (Division of Cardiology, Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine)
  • Received : 2018.08.02
  • Accepted : 2018.11.20
  • Published : 2018.12.27
⟨ Previous Next ⟩

Abstract

BACKGROUND: Statins are thought to have little effect on the progression of aortic stenosis, but the data on their role in patients with aortic valve sclerosis (AVS) are limited and inconsistent. METHODS: We retrospectively analyzed 541 consecutive patients (214 men, age: $70{\pm}11$ years) with AVS. Each patient underwent two or more electrocardiography examinations at least 6 months apart at Kangwon National University Hospital from August 2010 to August 2015. AVS is defined as irregular thickening of the leaflets, focal increases in echogenicity and minimal elevation of the peak aortic valve velocity (> 1.5 and < 2 m/s). The progression rate of AVS was expressed as the increase in peak velocity per year (m/s/yr). RESULTS: The mean follow-up duration was $24.9{\pm}13.3$ months in the statin-treated group and $24.1{\pm}12.4$ months in the non-statin-treated group (p = 0.460). There were no differences between the statin-treated and non-statin-treated groups in mean age, gender or smoking status. Relative to the non-statin-treated group, a higher number of patients in the statin-treated group had hypertension, diabetes, ischemic heart disease, and stroke. The progression rate of AVS did not differ between the statin-treated and non-statin-treated groups ($0.012{\pm}0.340m/s/yr$ vs. $0.014{\pm}0.245m/s/yr$, p = 0.956). Multivariate analysis showed initial peak aortic jet velocity was significantly associated with AVS progression (${\beta}=0.153$, p = 0.009). CONCLUSIONS: Our study demonstrated that statins had no effect on the progression of AVS. However, well-designed studies are needed to define the prognosis and management of AVS.

Keywords

References

  1. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005;111:3316-26. https://doi.org/10.1161/CIRCULATIONAHA.104.486738
  2. Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993;21:1220-5. https://doi.org/10.1016/0735-1097(93)90249-Z
  3. Rossebo AB, Pedersen TR. Hyperlipidaemia and aortic valve disease. Curr Opin Lipidol 2004;15:447-51. https://doi.org/10.1097/01.mol.0000137229.00020.fe
  4. Wierzbicki A, Shetty C. Aortic stenosis: an atherosclerotic disease? J Heart Valve Dis 1999;8:416-23.
  5. Liebe V, Brueckmann M, Borggrefe M, Kaden JJ. Statin therapy of calcific aortic stenosis: hype or hope? Eur Heart J 2006;27:773-8. https://doi.org/10.1093/eurheartj/ehi697
  6. Rajamannan NM, Subramaniam M, Springett M, et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 2002;105:2660-5. https://doi.org/10.1161/01.CIR.0000017435.87463.72
  7. Akin I, Nienaber CA. Is there evidence for statins in the treatment of aortic valve stenosis? World J Cardiol 2017;9:667-72. https://doi.org/10.4330/wjc.v9.i8.667
  8. Antonini-Canterin F, Popescu BA, Huang G, et al. Progression of aortic valve sclerosis and aortic valve stenosis: what is the role of statin treatment? Ital Heart J 2005;6:119-24.
  9. Hamilton AM, Boughner DR, Drangova M, Rogers KA. Statin treatment of hypercholesterolemic-induced aortic valve sclerosis. Cardiovasc Pathol 2011;20:84-92. https://doi.org/10.1016/j.carpath.2010.01.004
  10. Memon S, Ganga HV, Masrur S, Thompson PD. The effect of HMG CoA reductase inhibitors on the progression of aortic sclerosis: review article. Conn Med 2016;80:169-74.
  11. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009;22:1-23, quiz 101-2. https://doi.org/10.1016/j.echo.2008.11.029
  12. Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001;88:693-5. https://doi.org/10.1016/S0002-9149(01)01821-5
  13. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002;40:1723-30. https://doi.org/10.1016/S0735-1097(02)02496-8
  14. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001;104:2205-9. https://doi.org/10.1161/hc4301.098249
  15. Rosenhek R, Rader F, Loho N, et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004;110:1291-5. https://doi.org/10.1161/01.CIR.0000140723.15274.53
  16. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007;49:554-61. https://doi.org/10.1016/j.jacc.2006.07.072
  17. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56. https://doi.org/10.1056/NEJMoa0804602
  18. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-97. https://doi.org/10.1056/NEJMoa043876
  19. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J; ASTRONOMER Investigators. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010;121:306-14. https://doi.org/10.1161/CIRCULATIONAHA.109.900027
  20. Parolari A, Tremoli E, Cavallotti L, et al. Do statins improve outcomes and delay the progression of non-rheumatic calcific aortic stenosis? Heart 2011;97:523-9. https://doi.org/10.1136/hrt.2010.215046
  21. Antonini-Canterin F, Hirsu M, Popescu BA, et al. Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis. Am J Cardiol 2008;102:738-42. https://doi.org/10.1016/j.amjcard.2008.04.056
  22. Ryu DR, Park SJ, Han H, et al. Progression rate of aortic valve stenosis in korean patients. J Cardiovasc Ultrasound 2010;18:127-33. https://doi.org/10.4250/jcu.2010.18.4.127
  23. Sashida Y, Rodriguez CJ, Boden-Albala B, et al. Ethnic differences in aortic valve thickness and related clinical factors. Am Heart J 2010;159:698-704. https://doi.org/10.1016/j.ahj.2009.12.031
  24. Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 2000;101:2497-502. https://doi.org/10.1161/01.CIR.101.21.2497
  25. Bahler RC, Desser DR, Finkelhor RS, Brener SJ, Youssefi M. Factors leading to progression of valvular aortic stenosis. Am J Cardiol 1999;84:1044-8. https://doi.org/10.1016/S0002-9149(99)00496-8
  26. Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000;343:611-7. https://doi.org/10.1056/NEJM200008313430903